Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

From sweeping curves to industrial structures, visionary architects have reimagined museums as more than just spaces to view ...

Guggenheim reaffirmed their buy rating on shares of CyberArk Software (NASDAQ:CYBR – Free Report) in a research note issued ...

Investing.com -- Maze Therapeutics Inc (NASDAQ: MAZE ) received bullish coverage from multiple analysts, with Guggenheim, ...

Here is the full schedule for MLB games on FOX this season with key dates and broadcast information: All games will be ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Marvel announces the Bring on the Bad Guys event crossover, which occurs across seven one-shots headlined by its most iconic ...

It was not your typical smash-and-grab burglary and the booty was precious: a toilet worth more than its weight in gold.